Walleye Capital LLC Crispr Therapeutics Ag Call Options Transaction History

Walleye Capital LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$51.17 - $68.18 $163,744 - $218,176	-3,200 Reduced 6.61%	45,200 $2.44 Million
Q1 2024 May 15, 2024	BUY	$60.67 - $89.12 $1.49 Million - $2.19 Million	24,600 Added 103.36%	48,400 $3.3 Million
Q4 2023 Feb 14, 2024	BUY	$38.62 - $72.18 $131,308 - $245,412	3,400 Added 16.67%	23,800 $1.49 Million
Q3 2023 Nov 14, 2023	SELL	$45.39 - $59.0 $108,936 - $141,600	-2,400 Reduced 10.53%	20,400 $925,000
Q1 2023 May 15, 2023	SELL	$41.0 - $56.12 $274,700 - $376,004	-6,700 Reduced 22.71%	22,800 $1.03 Million
Q4 2022 Feb 14, 2023	BUY	$39.19 - $65.67 $407,576 - $682,968	10,400 Added 54.45%	29,500 $1.2 Million
Q3 2022 Nov 14, 2022	BUY	$61.1 - $83.78 $1.17 Million - $1.6 Million	19,100 New	19,100 $1.25 Million
Q4 2019 Feb 14, 2020	SELL	$36.68 - $73.13 $352,128 - $702,048	-9,600 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$40.99 - $52.56 $94,277 - $120,888	2,300 Added 31.51%	9,600 $394,000
Q2 2019 Aug 14, 2019	SELL	$35.45 - $48.2 $17,725 - $24,100	-500 Reduced 6.41%	7,300 $344,000
Q1 2019 May 15, 2019	BUY	$28.02 - $40.87 $218,556 - $318,786	7,800 New	7,800 $279,000

523

58M

1.73M

1.84M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.87B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.